| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PKCq |
| Uniprot No | O76003 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-335aa |
| 氨基酸序列 | MAAGAAEAAVAAVEEVGSAGQFEELLRLKAKSLLVVHFWAPWAPQCAQMNEVMAELAKELPQVSFVKLEAEGVPEVSEKYEISSVPTFLFFKNSQKIDRLDGAHAPELTKKVQRHASSGSFLPSANEHLKEDLNLRLKKLTHAAPCMLFMKGTPQEPRCGFSKQMVEILHKHNIQFSSFDIFSDEEVRQGLKAYSSWPTYPQLYVSGELIGGLDIIKELEASEELDTICPKAPKLEERLKVLTNKASVMLFMKGNKQEAKCGFSKQILEILNSTGVEYETFDILEDEEVRQGLKAYSNWPTYPQLYVKGELVGGLDIVKELKENGELLPILRGEN |
| 预测分子量 | 64.3kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PKCθ重组蛋白的参考文献摘要示例：
---
1. **Title**: "Protein kinase C-θ is critical for T-cell receptor-mediated NF-κB activation"
**Author**: Altman, A., Isakov, N., & Baier, G.
**摘要**: 该研究利用重组PKCθ蛋白，揭示了其在T细胞受体(TCR)信号传导中的核心作用，证明PKCθ通过激活NF-κB通路调控T细胞活化和免疫响应，为自身免疫疾病治疗提供新靶点。
---
2. **Title**: "Structural basis of protein kinase Cθ regulation by phosphorylation"
**Author**: Freeley, M., & Kelleher, D.
**摘要**: 通过重组表达并纯化PKCθ激酶结构域，结合X射线晶体学分析，阐明了PKCθ磷酸化修饰对其催化活性和构象变化的调控机制，为设计特异性抑制剂奠定结构基础。
---
3. **Title**: "PKCθ interacts with Vav1 to regulate actin cytoskeleton dynamics in T cells"
**Author**: Villalba, M., & Bi, K.
**摘要**: 研究利用重组PKCθ和Vav1蛋白进行体外结合实验，证明两者在T细胞中形成复合物并协同调控肌动蛋白重组，影响免疫突触形成和细胞迁移功能。
---
4. **Title**: "Recombinant PKCθ kinase domain production for high-throughput drug screening"
**Author**: Liu, Y., & Huang, C.
**摘要**: 开发了重组PKCθ激酶结构域的高效表达纯化系统，用于大规模药物筛选，鉴定出多个选择性小分子抑制剂，为炎症性疾病和癌症治疗提供候选化合物。
---
注：以上为模拟摘要，实际文献需通过PubMed/Google Scholar检索确认。
Protein kinase C theta (PKCθ) is a serine/threonine kinase belonging to the protein kinase C (PKC) family, specifically classified under the novel PKC subfamily due to its calcium-independent activation and dependence on diacylglycerol (DAG) for signaling. Discovered in the 1990s, PKCθ is predominantly expressed in T lymphocytes, skeletal muscle, and platelets, distinguishing it from other PKC isoforms. It plays a critical role in immune regulation, particularly in T-cell receptor (TCR)-mediated signaling, where it localizes to the immunological synapse during antigen presentation. This kinase is essential for activating transcription factors like NF-κB and AP-1. which regulate T-cell proliferation, cytokine production, and survival. Dysregulation of PKCθ has been implicated in autoimmune diseases, allergies, and cancer, making it a therapeutic target.
Recombinant PKCθ proteins are engineered using expression systems (e.g., insect or mammalian cells) to ensure proper post-translational modifications and functional activity. These proteins retain catalytic domains (C3/C4 for kinase activity) and regulatory domains (C1 for DAG binding, C2 for membrane interaction), enabling in vitro studies of enzyme kinetics, substrate interactions, and inhibitor screening. Researchers utilize PKCθ recombinant proteins to dissect signaling pathways, develop targeted therapies, and study mechanisms underlying immune disorders. Its role in modulating T-cell anergy and tolerance further highlights its relevance in immunotherapy research. Advances in structural studies of recombinant PKCθ have also facilitated the design of selective inhibitors, offering potential treatments for conditions like rheumatoid arthritis or graft-versus-host disease while minimizing off-target effects.
×
